BigHat Biosciences
PrivateLast Round
Series C
Sep 23, 2026
Est. Valuation
$304.1M
Total Funding Raised
$303.8M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
BigHat Biosciences is a biotechnology company that develops AI-guided protein therapeutic platforms to engineer safer and more effective antibody therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BigHat Biosciences Comparables
Compare BigHat Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nabla Bio | 84% | |
| Earendil Labs | 84% | |
| Generate Biomedicines | 82% |
BigHat Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 23, 2026 | ||||
| Series B | Apr 28, 2025 | ||||
| Series B | Jul 20, 2022 | ||||
| Series A | Feb 10, 2021 | ||||
| Grant | Nov 1, 2020 | ||||
Seed | Oct 22, 2019 |
Key People
Founding team and executive leadership
BigHat Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B, Series C, Series A |
| S32 | Series C, Series B |
| Innovation Endeavors | Series A, Seed |
| Gaingels | Series B |
| M Ventures | Series B, Series A |
| LG Technology Ventures | Series C |
| Intermountain Ventures | Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 23, 2026
$75M round led by DFJ Growth and Premji Invest.
- Apr 28, 2025
$124M round raised at $304M post-money valuation.
Recent news
Latest coverage and updates
- is_developingSep 25, 2026
BigHat Bio is developing AI-native system for designing protein therapeutics
- receives_financingSep 24, 2026
On Sep 24th '26 in California, BigHat Bio completed its $75M Series C financing, co-led by DFJ Growth and Premji Invest, to scale its AI-driven protein design platform and advance its AI-designed therapeutics pipeline.
- is_developingSep 1, 2026
BigHat Bio is developing AI platform on Sep 1st '26
BigHat Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BigHat Biosciences's valuation, stock price, and market status.
Is BigHat Biosciences a public or private company?
BigHat Biosciences is a private company.
What is the current stock price of BigHat Biosciences?
BigHat Biosciences is a private company, so its shares have no public market price. Caplight tracks BigHat Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BigHat Biosciences worth (valuation)?
BigHat Biosciences's valuation is estimated at $304.1M based on funding round data.
Can I buy BigHat Biosciences stock?
BigHat Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BigHat Biosciences's last funding round?
BigHat Biosciences's most recent funding round was Series C on September 23, 2026.
Who are the main investors in BigHat Biosciences?
Key investors in BigHat Biosciences include Andreessen Horowitz, S32, DFJ Growth, Premji Invest, 8VC.
Will BigHat Biosciences IPO soon?
No public IPO plans have been announced for BigHat Biosciences.
How can I track BigHat Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in BigHat Biosciences's shares on secondary markets.